INBX

Inhibrx Biosciences, Inc. (INBX) | Rumor.io

Inhibrx Biosciences

INBX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,179

Bullish sentiment (50-day avg)80%

Price to earnings ratio0.2

Market capitalization1.5B

Earnings per share-8.88

Dividend yield (TTM)—

Revenue (annual)1.3M

Net income (annual)-140.1M

Social

What share of all stock conversation is about INBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 8

$INBX's INBRX-106 achieved an interim median PFS of 9.6 months in a Phase 2 HNSCC study, with a 48.3% combined overall response rate (cORR) when combined with pembrolizumab.
The results were most pronounced in HPV+ patients, with a cORR of 80.0% and CR rate of 30.0%, compared to pembrolizumab alone.
Inhibrx plans to expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approval.

Generated by AI

Sentiment

Of the messages about INBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	87.5% new	71.58% -27.55	82.62% -17.38
Bearish	—	12.5% -87.5	28.42% +27.55	17.38% +17.38

Bullish· May 11

The company's INBRX-106 has shown promising interim results in a Phase 2 trial, with a 44.0% complete response rate (cORR) when combined with Keytruda, compared to 21.4% for Keytruda alone.
The data suggests that INBRX-106 is adding real clinical and biological benefit on top of Keytruda, with deeper tumor shrinkage and up to 15x T-cell proliferation compared to 2.5x with Keytruda.
The market is undervaluing INBX, with one analyst indicating fair value is $330 and a potential price target of $500 by the end of the year, suggesting significant upside potential.

Bearish· Oct 24

The asset's price is experiencing significant volatility, with some posts suggesting it may drop to $42.70 or even $45/26.
The company's recent liver toxicity concerns may lead to additional trials and CRL (Clinical Hold) issues, potentially impacting the asset's value.
The asset's historical price trend suggests it may be due for a correction, with some posters arguing it's a short play at current levels.

Generated by AI

Topics

Of the messages about INBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	68.49%
Analysts	—	0%	0%	10.74%
Technical Analysis	—	0%	0%	13.89%
Earnings	—	0%	0%	0.21%
Controversies	—	0%	0%	0.7%
Macro	—	0%	0%	5.96%

Announcements· Apr 22

Inhibrx Biosciences $INBX is trading near historic highs due to breakthrough clinical data and major regulatory milestones for its lead cancer drug ozekibart (INBRX-109).
Inhibrx Biosciences has attracted takeover interest from major pharmaceutical companies, including Merck & Co, Merck KGaA, and Ono Pharmaceutical, for its experimental cancer treatments, particularly INBRX-106, which could be valued at over $9 billion.
Inhibrx Biosciences reported interim data from its Phase 1/2 study of ozekibart, showing a 20% response rate in patients with advanced colorectal cancer, significantly higher than the current standard of care.

Technical Analysis· Apr 22

$INBX has broken through key resistance levels, with significant volume and price gains, and is now targeting $15455.95.
The stock's explosive move is driven by Merck's interest in its asset related to Keytruda, and has resulted in a 36.72% increase to $11495.00.
With a short interest of 20.7% and 9.54 days to cover, $INBX is at high risk for a short squeeze, which could lead to a massive move.

Generated by AI

Community

Of the messages about INBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	19.51%	64.4%	57.72%
Newcomers	100%	80.49%	35.6%	42.28%

Regulars· Sep 8

The interim results for INBRX-106 show a 48.3% complete response rate and 72.4% of patients remain progression-free at 6 months, outperforming pembrolizumab alone.
The CEO's confidence in INBRX-106's peri-operative NSCLC data, expected mid-2027, is notable given the limited monotherapy activity of pembrolizumab in this area.
The validation of INBRX-106's OX40 agonism with 9.6 months interim median PFS in Phase 2 HNSCC study suggests the asset's potential, despite the negative short-term market reaction.

Newcomers· Sep 8

CEO Mark Lappe's recent purchase of 25,000 shares at $105.82 is seen as a strong bullish signal, indicating executives' confidence in the company's future.
The Phase 2 study of INBRX-106 nearly doubles response rate and achieves an interim median PFS of 9.6 months in HNSCC, with positive results most pronounced in HPV+ patients.
The company is expected to release final results from the expanded Phase 2 study, potentially leading to accelerated approval and expansion opportunities into highly immunogenic tumors.

Generated by AI

Inhibrx Biosciences (INBX) has drawn investor attention after a sharp move in the share price. The US$101.71 close now sits alongside a year-to-date gain of about 35%. Recent trading has been choppy, with a 1-day share price return of 2.11% following a 7-day share price return that fell 9.22% and a 30-day share price return down 17.58%. Despite this, Inhibrx Biosciences still shows a year-to-date share price return of 35.54% and a very large 1-year total shareholder return of 214.79%. This...

1d agoYahoo Finance

Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock

1d agoInvesting.com

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

Inhibrx Biosciences, Inc. (NASDAQ:INBX) delivered the kind of clinical update that would normally be expected to get investors’ attention. Its experimental cancer drug INBRX-106, combined with Merck’s Keytruda, produced a confirmed response rate nearly twice that of Keytruda alone in a Phase 2 head and neck cancer study. The results were even stronger among a […]

5d agoYahoo Finance

Also Discussed

Investors talking about INBX also mention

#	Name	Attention
1	F/m 3-Year Investment Grade Corporate Bond ETFZTRE	0%0
2	Huntington Bancshares Incorporated - Depositary Shares, Each Representing a 1/40th Interest in a Share of 6.875% Series J Non-Cumulative Perpetual Preferred StockHBANL	0%new
3	Olema Pharmaceuticals, Inc.OLMA	0%new
4	Invesco BulletShares 2026 Corporate Bond ETFBSCQ	0%0
5	Alumis Inc.ALMS	0%0
6	DICE - DICE Therapeutics, Inc.	——
7	Abivax SAABVX	0.01%-0.01
8	Neuphoria Therapeutics Inc.NEUP	0%0
9	Harrow Inc.HROW	0%0
10	Zentalis Pharmaceuticals, Inc.ZNTL	0%new

Inhibrx Biosciences, Inc.

Healthcare
Biotechnology

Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing engineered biologic therapies for oncology and other serious diseases. Inhibrx Biosciences uses proprietary protein engineering platforms to design multivalent therapeutic candidates that are intended to interact precisely with complex biological targets. Its current pipeline centers on ozekibart (INBRX-109) and INBRX-106, programs being advanced in clinical studies across solid tumors and rare cancer settings. The company’s work is directed toward creating targeted medicines that address difficult-to-treat conditions through differentiated biologic mechanisms. Headquartered in La Jolla, California, Inhibrx Biosciences plays a specialized role in the biopharmaceutical market as a developer of precision protein-based therapeutics.

Website

Location

11025 North Torrey Pines Road

La Jolla, CA, 92037

United States

Social

What share of all stock conversation is about INBX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% +0

Sep 8

$INBX's INBRX-106 achieved an interim median PFS of 9.6 months in a Phase 2 HNSCC study, with a 48.3% combined overall response rate (cORR) when combined with pembrolizumab.
The results were most pronounced in HPV+ patients, with a cORR of 80.0% and CR rate of 30.0%, compared to pembrolizumab alone.
Inhibrx plans to expand the Phase 2 study by approximately 50 HPV+ patients and may serve as a potential pathway to accelerated approval.

Generated by AI

Sentiment

Of the messages about INBX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	87.5% new	71.58% -27.55	82.62% -17.38
Bearish	—	12.5% -87.5	28.42% +27.55	17.38% +17.38

Bullish· May 11

The company's INBRX-106 has shown promising interim results in a Phase 2 trial, with a 44.0% complete response rate (cORR) when combined with Keytruda, compared to 21.4% for Keytruda alone.
The data suggests that INBRX-106 is adding real clinical and biological benefit on top of Keytruda, with deeper tumor shrinkage and up to 15x T-cell proliferation compared to 2.5x with Keytruda.
The market is undervaluing INBX, with one analyst indicating fair value is $330 and a potential price target of $500 by the end of the year, suggesting significant upside potential.

Bearish· Oct 24

The asset's price is experiencing significant volatility, with some posts suggesting it may drop to $42.70 or even $45/26.
The company's recent liver toxicity concerns may lead to additional trials and CRL (Clinical Hold) issues, potentially impacting the asset's value.
The asset's historical price trend suggests it may be due for a correction, with some posters arguing it's a short play at current levels.

Generated by AI

Topics

Of the messages about INBX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	100%	100%	68.49%
Analysts	—	0%	0%	10.74%
Technical Analysis	—	0%	0%	13.89%
Earnings	—	0%	0%	0.21%
Controversies	—	0%	0%	0.7%
Macro	—	0%	0%	5.96%

Announcements· Apr 22

Inhibrx Biosciences $INBX is trading near historic highs due to breakthrough clinical data and major regulatory milestones for its lead cancer drug ozekibart (INBRX-109).
Inhibrx Biosciences has attracted takeover interest from major pharmaceutical companies, including Merck & Co, Merck KGaA, and Ono Pharmaceutical, for its experimental cancer treatments, particularly INBRX-106, which could be valued at over $9 billion.
Inhibrx Biosciences reported interim data from its Phase 1/2 study of ozekibart, showing a 20% response rate in patients with advanced colorectal cancer, significantly higher than the current standard of care.

Technical Analysis· Apr 22

$INBX has broken through key resistance levels, with significant volume and price gains, and is now targeting $15455.95.
The stock's explosive move is driven by Merck's interest in its asset related to Keytruda, and has resulted in a 36.72% increase to $11495.00.
With a short interest of 20.7% and 9.54 days to cover, $INBX is at high risk for a short squeeze, which could lead to a massive move.

Generated by AI

Community

Of the messages about INBX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	19.51%	64.4%	57.72%
Newcomers	100%	80.49%	35.6%	42.28%

Regulars· Sep 8

The interim results for INBRX-106 show a 48.3% complete response rate and 72.4% of patients remain progression-free at 6 months, outperforming pembrolizumab alone.
The CEO's confidence in INBRX-106's peri-operative NSCLC data, expected mid-2027, is notable given the limited monotherapy activity of pembrolizumab in this area.
The validation of INBRX-106's OX40 agonism with 9.6 months interim median PFS in Phase 2 HNSCC study suggests the asset's potential, despite the negative short-term market reaction.

Newcomers· Sep 8

CEO Mark Lappe's recent purchase of 25,000 shares at $105.82 is seen as a strong bullish signal, indicating executives' confidence in the company's future.
The Phase 2 study of INBRX-106 nearly doubles response rate and achieves an interim median PFS of 9.6 months in HNSCC, with positive results most pronounced in HPV+ patients.
The company is expected to release final results from the expanded Phase 2 study, potentially leading to accelerated approval and expansion opportunities into highly immunogenic tumors.

Generated by AI

Inhibrx Biosciences

Social

Sep 8

Bullish· May 11

Bearish· Oct 24

Announcements· Apr 22

Technical Analysis· Apr 22

Regulars· Sep 8

Newcomers· Sep 8

Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating

Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock

Citizens reiterates Market Perform on Inhibrx Biosciences stock

Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock

Also Discussed

Inhibrx Biosciences, Inc.

Company Information

Location

Inhibrx Biosciences (INBX) Faces A Pipeline Valuation Test Following Its Sharp Rerating

Inhibrx Biosciences CEO Mark Lappe buys $998k in company stock

Inhibrx’s Cancer Drug Nearly Doubled Response Rate, So Why Did the Stock Fall?

Inhibrx Biosciences director Jon Kayyem buys $500,000 in common stock

Citizens reiterates Market Perform on Inhibrx Biosciences stock

Inhibrx Biosciences director Jon Kayyem buys $500,000 in stock

Also Discussed

Social

Sep 8

Bullish· May 11

Bearish· Oct 24

Announcements· Apr 22

Technical Analysis· Apr 22

Regulars· Sep 8

Newcomers· Sep 8